|
52 Companies |
|
55 Products |
|
55 Products |
|
44 Mechanisms of Action |
|
2 Trials |
|
148 News |
|
| «123 |
- Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial withdrawal: Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 22, 2013
P=N/A, N=0, Withdrawn, Sponsor: Comprehensive Cancer Center of Wake Forest University
Suspended --> Withdrawn
- Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Enrollment change: Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 22, 2013
P=N/A, N=0, Withdrawn, Sponsor: Comprehensive Cancer Center of Wake Forest University
Suspended --> Withdrawn N=30 --> 0
- bortezomib / Generic mfg.
Enrollment closed: Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission (clinicaltrials.gov) - Sep 8, 2013
P2, N=35, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
N=30 --> 0 Recruiting --> Active, not recruiting
- Enrollment closed, Combination therapy: Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 27, 2013
P1, N=22, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Enrollment open: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia (clinicaltrials.gov) - Aug 14, 2013
P=N/A, N=30, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- HEOR: Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia (clinicaltrials.gov) - Jul 25, 2013
P=N/A, N=0, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
- ||| vadastuximab talirine (SGN-CD33A) / Pfizer
New P1 trial: A Safety Study of SGN-CD33A in AML Patients (clinicaltrials.gov) - Jul 16, 2013
P1, N=96, Recruiting, Sponsor: Seattle Genetics, Inc.
- ||| vadastuximab talirine (SGN-CD33A) / Pfizer
Enrollment open: A Safety Study of SGN-CD33A in AML Patients (clinicaltrials.gov) - Jul 14, 2013
P1, N=96, Recruiting, Sponsor: Seattle Genetics, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- 7-Hydroxystaurosporine (UCN-01) / National Cancer Institute
Trial completion, Combination therapy: 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes (clinicaltrials.gov) - Jun 30, 2013
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
Enrollment closed: Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 16, 2013
P1, N=36, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial termination: Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler (clinicaltrials.gov) - May 26, 2013
P=N/A, N=264, Terminated, Sponsor: Skyline Diagnostics BV
Recruiting --> Terminated; The required number of banked samples could not be met due to limited availability. There is no realistic possibility to complete the study succesfully.
- Enrollment change: Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler (clinicaltrials.gov) - May 26, 2013
P=N/A, N=264, Terminated, Sponsor: Skyline Diagnostics BV
There is no realistic possibility to complete the study succesfully. N=545 --> 264
- arsenic trioxide / Generic mfg.
Trial initiation date: Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia (clinicaltrials.gov) - Apr 10, 2013
P1/2, N=13, Completed, Sponsor: Washington University School of Medicine
N=545 --> 264 Initiation date: May 1998 --> Nov 1998
- arsenic trioxide / Generic mfg.
Enrollment change: Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia (clinicaltrials.gov) - Apr 10, 2013
P1/2, N=13, Completed, Sponsor: Washington University School of Medicine
Initiation date: May 1998 --> Nov 1998 N=32 --> 13
- Istodax (romidepsin) / Astellas, BMS
Trial completion: Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 10, 2013
P2, N=47, Completed, Sponsor: National Cancer Institute (NCI)
N=32 --> 13 Active, not recruiting --> Completed
- arsenic trioxide / Generic mfg.
Trial completion: Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia (clinicaltrials.gov) - Apr 10, 2013
P1/2, N=13, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Combination therapy: Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders (clinicaltrials.gov) - Apr 9, 2013
P1, N=25, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Combination therapy: Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) - Mar 31, 2013
P1, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Suspended --> Completed
- lenalidomide / Generic mfg.
Enrollment change: Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers (clinicaltrials.gov) - Mar 25, 2013
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed N=90 --> 60
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap
Trial completion: Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer (clinicaltrials.gov) - Mar 20, 2013
P2, N=40, Completed, Sponsor: Cancer Treatment Centers of America
N=90 --> 60 Active, not recruiting --> Completed
- Beleodaq (belinostat) / Aurobindo, Assertio
Enrollment closed, Combination therapy, Metastases: Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases (clinicaltrials.gov) - Mar 17, 2013
P1, N=33, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- arsenic trioxide / Generic mfg., idarubicin hydrochloride / Generic mfg.
Enrollment change, IO biomarker: Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia (clinicaltrials.gov) - Mar 14, 2013
P2, N=1, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting N=39 --> 1
- Synribo (omacetaxine mepesuccinate) / Teva
Enrollment change: Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia (clinicaltrials.gov) - Mar 6, 2013
P1/2, N=0, Withdrawn, Sponsor: National Cancer Institute (NCI)
N=39 --> 1 N=20 --> 0
- | Amnolake (tamibarotene) / Syros
Enrollment change: STAR-1: Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL (clinicaltrials.gov) - Feb 10, 2013
P2, N=15, Completed, Sponsor: CytRx
N=20 --> 0 N=50 --> 15
- | Amnolake (tamibarotene) / Syros
Trial completion: STAR-1: Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL (clinicaltrials.gov) - Feb 10, 2013
P2, N=15, Completed, Sponsor: CytRx
N=50 --> 15 Recruiting --> Completed
- decitabine / Generic mfg.
Trial termination: Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 21, 2013
P1, N=21, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Completed --> Terminated; Administratively complete.
- cyclophosphamide / Generic mfg.
Enrollment change: Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML) (clinicaltrials.gov) - Jan 21, 2013
P2, N=88, Completed, Sponsor: Stanford University
Completed --> Terminated; Administratively complete. N=175 --> 88
- | Enrollment change: Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia (clinicaltrials.gov) - Dec 18, 2012
P3, N=420, Completed, Sponsor: National Cancer Institute (NCI)
N=175 --> 88 N=582 --> 420
- | Trial completion: Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia (clinicaltrials.gov) - Dec 18, 2012
P3, N=420, Completed, Sponsor: National Cancer Institute (NCI)
N=582 --> 420 Active, not recruiting --> Completed
- dilanubicel (DVX101) / Deverra Therapeutics
Enrollment open: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 16, 2012
P=N/A, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant (clinicaltrials.gov) - Dec 9, 2012
P2, N=0, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; low accrual
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment closed, Epigenetic controller: Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 2, 2012
P2, N=196, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; low accrual Recruiting --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD)
Trial initiation date: Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Nov 18, 2012
P1, N=36, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Initiation date: Nov 2009 --> May 2010
- lenalidomide / Generic mfg.
Enrollment closed: Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers (clinicaltrials.gov) - Nov 14, 2012
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Nov 2009 --> May 2010 Suspended --> Active, not recruiting
- sorafenib / Generic mfg.
Enrollment change: Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Nov 7, 2012
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting N=55 --> 36
- | amphotericin b liposome / Generic mfg.
Enrollment change: Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients (clinicaltrials.gov) - Sep 19, 2012
P3, N=115, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=55 --> 36 N=450 --> 115
- | amphotericin b liposome / Generic mfg.
Trial completion: Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients (clinicaltrials.gov) - Sep 19, 2012
P3, N=115, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=450 --> 115 Active, not recruiting --> Completed
- ispinesib (SB-715992) / Cytokinetics
Trial completion, Metastases: SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes (clinicaltrials.gov) - Sep 10, 2012
P1, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- dilanubicel (NLA101) / Nohla Therap
Enrollment closed, Combination therapy: Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 3, 2012
P1, N=40, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Active, not recruiting --> Completed Suspended --> Active, not recruiting
- Enrollment change: Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 5, 2012
P2, N=280, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Suspended --> Active, not recruiting N=40 --> 280
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed: Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant (clinicaltrials.gov) - Mar 30, 2012
P2, N=88, Active, not recruiting, Sponsor: Cancer and Leukemia Group B
N=40 --> 280 Recruiting --> Active, not recruiting
- bortezomib / Generic mfg.
New P2 trial: Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission (clinicaltrials.gov) - Nov 2, 2011
P2, N=35, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- Biomarker, Trial completion: Biomarkers in Tissue Samples From Patients With Acute Promyelocytic Leukemia (clinicaltrials.gov) - Oct 24, 2011
P=N/A, N=10, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- busulfan / Generic mfg., idarubicin hydrochloride / Generic mfg.
Enrollment open: ASCT for Relapsed APL After Molecular Remission (clinicaltrials.gov) - Sep 14, 2011
P2, N=30, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Active, not recruiting --> Completed Not yet recruiting --> Recruiting